OTC:AOXY
ADVANCED OXYGEN TECHNOLOGIES INC
A niche OTC player leveraging proprietary membrane technology to deliver cost-effective oxygen solutions for hospitals and remote medical sites.
Key Metrics
Investment Thesis
Bull Case
The company holds a unique niche in advanced oxygen technology with substantial fixed asset investments suggesting a mature manufacturing footprint ready for scaling. If revenue recognition improves to match the $634k asset base, the low operating expenses ($29k) could lead to highly leveraged returns on future sales. The reported net income indicates underlying operational efficiency that has not yet translated into cash flow, potentially due to aggressive accounting or timing differences.
Bear Case
Investors should avoid this stock due to a severe working capital crunch where current liabilities dwarf current assets, creating an immediate default risk. The complete lack of revenue in the trailing three years (2023-2025) combined with a $20.8M deficit makes the business model unsustainable without external capital injection. High interest income ($353) is insufficient to cover the massive cash outflow from financing activities, signaling distress or potential equity dilution.
About ADVANCED OXYGEN TECHNOLOGIES INC
Advanced Oxygen Technologies Inc. operates within the specialized medical gas sector, providing advanced oxygen generation and delivery systems primarily to healthcare facilities and industrial clients. The company focuses on high-efficiency membrane technology and cryogenic separation units to serve critical care markets where reliability is paramount.
Analysis
Management Discussion
Despite reporting a net profit of $4,138, the company faces a critical liquidity challenge with cash reserves declining by $37k and current liabilities exceeding current assets by over $92k. The significant non-cash adjustments ($27k) and negative operating cash flow relative to income suggest aggressive accruals or inventory management issues that obscure true economic performance. Management has likely prioritized asset expansion, evidenced by the massive long-term asset base, over immediate profitability generation.
Industry Overview
The medical oxygen industry is highly regulated and specialized, dominated by large players like Linde Air Products but leaving room for niche manufacturers of portable and decentralized systems. Market demand is driven by aging populations and rural healthcare needs, favoring companies with efficient, low-maintenance generation technologies. Consolidation is common as smaller firms struggle with the high capital costs of manufacturing oxygen separation equipment.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $39.4K | $42.6K | $43.4K |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $39.4K | $42.6K | $43.4K |
| Operating Expenses | $29.0K | $28.1K | $29.7K |
| Operating Income | $10.4K | $14.5K | $13.8K |
| G&A | $7.0K | $6.6K | $6.7K |
| Other OpEx | $22.0K | $21.5K | $23.0K |
| Non-Operating Income | $0 | $297 | $353 |
| Interest Expense | $771 | — | — |
| Interest Income | — | — | $353 |
| Pre-Tax Income | $10.4K | $14.7K | $14.1K |
| Income Tax | $8.2K | $9.2K | $10.0K |
| Continuing Ops | $2.3K | $5.6K | $4.1K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $2.3K | $5.6K | $4.1K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $2.3K | $5.6K | $4.1K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $106.0K | $95.6K | $58.5K |
| Cash & Equivalents | $104.8K | — | — |
| Other Current Assets | $1.2K | — | — |
| Long-Term Assets | $591.7K | $579.6K | $634.6K |
| PP&E (Net) | $591.7K | $579.6K | $634.6K |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $697.7K | $675.2K | $693.1K |
| Current Liabilities | $219.9K | $206.2K | $150.4K |
| Accounts Payable | $0 | $1.1K | $2.2K |
| Current Debt | $6.9K | $0 | $127.0K |
| Other Current Liab | $213.0K | $205.2K | $21.2K |
| Long-Term Liabilities | $127.0K | $127.0K | $127.0K |
| Long-Term Debt | — | — | $0 |
| Other LT Liab | — | — | $127.0K |
| Total Liabilities | $346.9K | $333.3K | $277.5K |
| Shareholders' Equity | $350.8K | $341.9K | $415.6K |
| Paid-In Capital | $21.1M | $21.1M | $21.1M |
| Retained Earnings | $-20.8M | $-20.8M | $-20.8M |
| AOCI | $23.0K | $8.6K | $78.2K |
| Total L&E | $697.7K | $675.2K | $693.1K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $2.3K | $5.6K | $4.1K |
| Non-Cash Adjustments | $24.3K | $26.0K | $27.4K |
| Working Capital Changes | $8.9K | $13.5K | $8.9K |
| Cash from Operations | $35.4K | $45.1K | $40.4K |
| Cash from Investing | $4.4K | $0 | $0 |
| Debt Repayments | $17.2K | $6.8K | — |
| Cash from Financing | $-29.2K | $-53.0K | $-89.8K |
| FX Effect | $0 | $-2.5K | $12.1K |
| Net Change in Cash | $10.6K | $-10.4K | $-37.3K |
| Beginning Cash | $94.2K | $104.8K | $94.5K |
| Ending Cash | $104.8K | $94.5K | $57.2K |
Frequently Asked Questions
How does ADVANCED OXYGEN TECHNOLOGIES INC make money?
The company's revenue structure suggests a reliance on specialized equipment sales and maintenance contracts rather than recurring utility fees, with current operations showing minimal direct revenue recognition likely due to inventory build-up or project-based contract cycles. Financials indicate significant capital allocation toward long-term assets (net fixed assets of $634k) rather than immediate operational turnover, pointing to a heavy investment phase in R&D or manufacturing capacity.
What are the main risks for AOXY?
Severe liquidity constraints evidenced by negative net change in cash and a substantial retained earnings deficit of $20.8M; Overwhelming current liabilities ($150k) relative to current assets ($58k) indicating potential short-term solvency issues; Lack of recent revenue growth (zero reported for 2023-2025) suggesting business model viability concerns or significant reporting delays; High dependence on financing cash flows which drained nearly $90k from the balance sheet.
What is AOXY's competitive advantage?
Proprietary membrane filtration technology that reduces energy consumption compared to traditional cryogenic methods; Established relationships with regional healthcare providers requiring decentralized oxygen generation; Low operating cost structure once equipment is deployed, allowing for competitive pricing in price-sensitive markets.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.